Compare NNBR & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNBR | IMMP |
|---|---|---|
| Founded | 1980 | 1987 |
| Country | United States | Australia |
| Employees | N/A | 51 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.8M | 76.6M |
| IPO Year | 1996 | 2012 |
| Metric | NNBR | IMMP |
|---|---|---|
| Price | $2.41 | $0.48 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | $3.00 | ★ $5.50 |
| AVG Volume (30 Days) | 1.0M | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.60 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $770,657,000.00 | N/A |
| Revenue This Year | $8.60 | $445.09 |
| Revenue Next Year | $6.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $0.29 |
| 52 Week High | $2.99 | $3.53 |
| Indicator | NNBR | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 55.21 | 42.91 |
| Support Level | $2.25 | $0.42 |
| Resistance Level | $2.58 | $1.05 |
| Average True Range (ATR) | 0.19 | 0.03 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 34.83 | 43.57 |
NN Inc is a diversified industrial company that combines engineering and production capabilities with materials science expertise to design and manufacture high-precision components and solutions. The company operates through two segments: Mobile Solutions, which generates maximum revenue and focuses on the automotive, general industrial, and medical end markets, manufacturing tight-tolerance components used in battery electric, hybrid electric, and internal combustion engine vehicles, braking, transmissions, fuel systems, HVAC, and diesel systems; and Power Solutions, which focuses on the electrical, general industrial, automotive, medical, and aerospace and defense end markets and manufactures high-precision metal components, assemblies, contact assemblies, and precision stampings.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.